1-5 of 5
Mark Pegram
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric Winer, Michael Naughton, Matthew P. Goetz, Christy Russell, Debu Tripathy, Melody Cobleigh, Andres Forero, Timothy J. Pluard, Carey Anders, Polly Ann Niravath, Shana Thomas, Jill Anderson, Caroline Bumb, Kimberly C. Banks, Richard B. Lanman, Richard Bryce, Alshad S. Lalani, John Pfeifer, Daniel F. Hayes, Mark Pegram, Kimberly Blackwell, Philippe L. Bedard, Hussam Al-Kateb, Matthew J.C. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5687–5695.
https://doi.org/10.1158/1078-0432.CCR-17-0900
Published: 01 October 2017
View article titled, Neratinib Efficacy and Circulating Tumor DNA Detection of <em>HER2</em> Mutations in <em>HER2</em> Nonamplified Metastatic Breast Cancer
Open the PDF for Neratinib Efficacy and Circulating Tumor DNA Detection of <em>HER2</em> Mutations in <em>HER2</em> Nonamplified Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer

Nuhad K. Ibrahim, Kemal O. Yariz, Ihor Bondarenko, Alexei Manikhas, Vladimir Semiglazov, Anna Alyasova, Volodymyr Komisarenko, Yaroslav Shparyk, James Lee Murray, David Jones, Shai Senderovich, Albert Chau, Fredrik Erlandsson, Gary Acton, Mark Pegram
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6822–6830.
https://doi.org/10.1158/1078-0432.CCR-11-1151
Published: 31 October 2011
View article titled, Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer
Open the PDF for Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer in another window
Journal Articles

Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

Clare Taylor, Dawn Hershman, Nina Shah, Nicole Suciu-Foca, Dan P. Petrylak, Robert Taub, Linda Vahdat, Bin Cheng, Mark Pegram, Keith L. Knutson, Raphael Clynes
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (17): 5133–5143.
https://doi.org/10.1158/1078-0432.CCR-07-0507
Published: 04 September 2007
View article titled, Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Open the PDF for Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy in another window
Journal Articles

HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer

Gottfried Konecny, Michael Untch, Jane Arboleda, Cindy Wilson, Stephen Kahlert, Berit Boettcher, Margrit Felber, Malgorzota Beryt, Sandra Lude, Hermann Hepp, Dennis Slamon, Mark Pegram
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2448–2457.
Published: 01 August 2001
View article titled, HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer
Open the PDF for HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer in another window
Journal Articles

Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer

Gottfried Konecny, Michael Untch, Astrid Pihan, Rainer Kimmig, Martina Gropp, Petra Stieber, Herrmann Hepp, Dennis Slamon, Mark Pegram
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (6): 1743–1749.
Published: 01 June 2001
View article titled, Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer
Open the PDF for Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer in another window